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Introduction
Porcine reproductive and respiratory syndrome
(PRRS) is one of the most relevant swine diseases, and
is characterized by reproductive failure in sows and
respiratory distress in pigs of all ages (Christianson
and Joo, 1994; Rossow, 1998). The causative agent,
PRRS virus (PRRSV), is a small, enveloped RNA virus
classified within the Arteriviridae family (Cavanagh,
1997) and divided into European and American subtypes
based on the high genetic, antigenic and pathogenic
heterogeneity among different viral isolates (Meng,
2000).
Nowadays, PRRSV has spread worldwide in major
swine-producing areas, becoming a severe swine health
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Abstract
The objective of this study was to determine the protective properties of the Spanish MLV vaccine Amervac-PRRS®
against porcine reproductive and respiratory syndrome virus (PRRSV) infection with the homologous wild-type strain
5710. The experimental design comprised eighteen 3-week old pigs randomly divided into three groups. Animals from
group A received one dose of MLV vaccine Amervac-PRRS on days –42 and –21. Animals from groups B and C served
as infected and uninfected controls, respectively. On day 0, pigs from groups A and B were intranasally challenged
with homologous strain 5710 and 18 days after challenge all pigs were euthanized. The results reported in this study
show that, although the titre of neutralizing antibodies elicited by vaccination was modest, MLV vaccine Amervac-PRRS®
provided protection against homologous PRRSV infection and drastically reduced post-challenge viremia and
completely block PRRSV dissemination to peripheral tissues.
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Resumen
Eficacia de una vacuna viva modificada española frente a la infección homóloga con el virus del síndrome
reproductor y respiratorio porcino
El objetivo de este estudio fue la determinación de las propiedades protectoras de la vacuna viva modificada espa-
ñola Amervac-PRRS® frente a la infección con la cepa homóloga 5710 del virus del síndrome reproductor y respira-
torio porcino (PRRSV). El estudio experimental incluyó dieciocho cerdos de tres semanas de edad divididos aleato-
riamente en tres grupos. Los animales del grupo A recibieron una dosis de la vacuna viva modificada Amervac-PRRS®
en los días –42 y –21. Los animales de los grupos B y C sirvieron como controles infectados y no infectados, respec-
tivamente. En el día 0 los cerdos de los grupos A y B fueron desafiados por vía intranasal con la cepa homóloga 5710
y 18 días después del desafío todos los cerdos fueron eutanasiados. Los resultados aportados en este estudio mues-
tran que, pese a que el título de anticuerpos neutralizantes inducido por la vacunación fue modesto, la vacuna viva
modificada Amervac-PRRS® proporcionó protección homóloga frente a la infección por el PRRSV y permitió redu-
cir drásticamente la viremia posterior al desafío y bloquear completamente la diseminación del PRRSV a tejidos pe-
riféricos.
Palabras clave adicionales: desafío homólogo, inmunización, porcino, protección frente a PRRSV.
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problem responsible for enormous economic losses.
In order to reduce the high impact of PRRSV in the swine
industry, different strategies have been designed from
sanitary to medical prophylaxis (Dee et al., 1998).
However, utilization of mere sanitary practices has not
provided successful results owing to PRRSV ability to
persist for weeks or months in asymptomatic hosts, even
in presence of PRRSV specific antibodies (Allende et
al., 2000). Consequently, vaccination strategies involving
inactivated and modified live virus (MLV) vaccines
have been developed to control the disease in fattening
pigs and breeding females. The high safety of inac-
tivated virus is the main advantage of this kind of
vaccines and the characteristic that permitted their
licence for use in pregnant females. However, the low
efficacy of these vaccines against PRRSV infection
has been confirmed (Osorio et al., 1998; Scortti et al.,
1999). To overcome the problem of efficacy, several
MLV vaccines have been developed. In this scenario,
MLV’s ability to replicate in vivo could improve vaccine
efficacy, inducing longer and more intense immune
response. However, MLV vaccines are not directed to
use in pregnant females and are approved to prevent
respiratory distress caused by PRRSV infection in young
piglets, fattening pigs and non-pregnant females. MLV
vaccines have shown to confer protection against
clinical manifestations of the disease, though they are
not capable of preventing from PRRSV infection. Most
of the eff icacy studies about current MLV vaccines
against PRRSV have been carried out using marketed
vaccines derived from the American PRRSV strain VR-
2332 (Gorcyca et al., 1995; Roof et al., 1999; Desrosiers,
2000; Nodelijk et al., 2001). Studies based on non-
commercial attenuated American PRRSV isolates have
been also performed showing the evolvement of a
complete homologous protection that could even avoid
PRRSV viremia and peripheral dissemination (Lager
et al., 1997, 1999; Mengeling et al., 2003). However these
studies can not be directly extrapolated to European
type viruses due to marked differences between both
types of PRRSV (Wensvoort et al., 1992; Murtaugh et
al., 1995; Meng, 2000). Little is known about the degree
of homologous protection provided by European MLV
vaccines currently on the market. Therefore, the
evolution of the immune response and the degree of
protection induced by these vaccines should be care-
fully evaluated in order to determine if they could
provide sterilizing homologous immunity.
The design of this study was aimed at determining
the protective properties of the Spanish MLV vaccine
Amervac-PRRS® (Hipra Laboratories, Spain), against
infection with the homologous wild-type PRRSV
strain 5710.
Material and Methods
Animals and facilities
Eighteen 3-weeks-old pigs without PRRSV serum
antibody titres measured by ELISA test (CIVTEST-
suisPRRS®, Hipra Laboratories, Spain) were included
in this experiment. The pigs were randomly divided into
3 groups, assigned to one treatment group and housed
in isolated pens with a concrete floor and automatic
watering system.
Vaccines
The commercial PRRSV MLV vaccine Amervac-
PRRS® was used for active immunization of pigs following
manufacturer’s instructions. This MLV vaccine is based
on a European-type strain (5710), belonging to Le-
lystad-like cluster, isolated in Spain in 1992 (Suárez
et al., 1994).
Virus and cell cultures
Challenge was performed with the Spanish PRRSV
strain 5710. This PRRSV strain was propagated on swine
alveolar macrophage (SAM) cultures prepared as
previously described (Prieto et al., 1997).
Evaluation of the presence of PRRSV in clinical sam-
ples collected before challenge was accomplished by
sample cultivation on MARC-145, a MA-104 cell
clone highly permissive to PRRSV (Kim et al., 1993),
and on SAM. Samples collected after challenge were
evaluated on SAM cultures prepared and maintained
as previously described (Prieto et al., 1997).
Experimental design and sample collection
The study comprised three experimental groups. Six
pigs (numbered 1 to 6) members of Group A were vacci-
nated twice by intramuscular route on days –42 and
–21 with the MLV vaccine Amervac PRRS®. Six pigs
of group B (numbered 7 to 12) and six pigs of group
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C (numbered 13 to 18) were not vaccinated and served
as infected and uninfected controls, respectively.
Three weeks after the second immunization (day 0)
pigs from groups A and B were challenged by intranasal
inoculation of 105 tissue culture infectious dose 50
(TCID50) of PRRSV strain 5710 prepared on primary
cultures of SAM, and pigs from group C were intra-
nasally inoculated with an uninfected SAM culture lysate.
All pigs were examined daily for clinical signs and
rectal temperatures were measured from 10 days before
challenge until the end of the experiment. Furthermore,
food intake, average daily gain (ADG) and food
conversion efficiency index (FCE) were recorded.
Blood samples were collected in serum-clot vacuum
tubes on each vaccination day and then 2, 7 and 14 days
post-vaccination, at challenge and 2, 5, 8, 12 and 18
days post-challenge (p.c.). Serum was obtained from
all blood samples and stored at –80ºC until its utili-
zation for virus isolation and PRRSV antibody detection.
Eighteen days after challenge (day +18) all pigs
were euthanized and tissue samples were collected,
namely lung, tonsils, kidney, spleen, liver and subman-
dibular, superficial iliac and retropharyngeal lymph
nodes. All these tissues were stored at –80ºC until they
were processed for virus isolation.
Virus isolation
The aliquots of sera obtained from the blood sam-
ples were thawed at room temperature, diluted 1:4 in
Dulbecco’s Modified Eagle’s Medium (DMEM) and
passed through a filter with 0.45 µm pores. One gram
of each tissue sample was homogenized with 9 ml of
DMEM, centrifuged at 1,200 g for 20 min at 4ºC and
supernatant was passed through a filter with 0.45 µm
pores.
All samples were added in quadruplicate (100 µl/well)
onto SAM or MARC-145 cell monolayers seeded in
96-well plates and incubated for 90 min at 37ºC to
facilitate adsorption. The cultures were washed twice
with DMEM and fresh DMEM containing 10% fetal
bovine serum (FBS) was added. The culture plates were
incubated at 37ºC in humidified atmosphere containing
5% CO2. Monolayers were examined for cytopathic
effect (CPE) on days 4, 5 and 6 post-inoculation.
As a positive control, PRRSV strain 5710 was added
to give a final concentration of 104, 103, 102 TCID50 ml–1
(i.e. 103, 102 and 10 TCID50/well). Only batches of SAM
with sensitivity to infection of at least 50% of the wells
in which 10 TCID50 had been introduced were used. Virus-
free DMEM was used as a negative control.
Serological examinations
Serum samples were examined for PRRSV-specific
antibodies using a commercial ELISA test (CIVTEST-
suisPRRS®, Hipra Laboratories, Spain). Serum samples
collected on vaccination days (days –42 and –21), at
challenge (day 0) and at the end of the experiment (day
+18) were tested using a neutralization assay perfor-
med onto MARC-145 cultures and following indications
previously described (Yoon et al., 1994).
Results
Clinical examination
Experimental immunization of the animals from
group A did not produce any local reaction or side effect.
After challenge, animals from group A remained healthy
and did not show detriment to productive parameters
(ADG, food consumption or FCE). However, animals
from group B had fever from day +2 (i.e. 2 days p.c.)
to day +6 (i.e. 6 days p.c.) and clinical signs such as
anorexia or lethargy between days +2 and +7 (i.e. 2
and 7 days p.c.). All animals belonging to group C re-
mained in normal health status during the experiment.
Detection of PRRSV in samples collected
from pigs
Before challenge, vaccine virus was isolated on SAM
from serum samples collected from pigs belonging to
group A from 7 days after the first vaccination to 14
days after the second one. However, post-vaccinal
viremia was detected earlier when virus isolation was
attempted on MARC-145 cell cultures, from 3 days
after the first vaccination to 14 days after the second one.
After challenge, PRRSV was only isolated from one
serum sample collected from group A on day +2 (i.e.
2 days p.c.) and from two sera on day +8 (i.e. 8 days
p.c.). Conversely, in group B all pigs remained viremic
from day +2 to the end of the experiment on day +18
(Table 1).
PRRSV was not detected from any of the tissue sam-
ples collected from pigs belonging to group A. Conver-
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sely, PRRSV was isolated from lung, spleen, tonsils
and lymph nodes (submandibular, iliac and retropha-
ryngeal lymph nodes) from pigs included in group B
(Table 2).
All sera and tissue samples collected from group C
were negative for virus isolation.
Serology
After immunization, specific PRRS antibodies were
detected by ELISA from group A 21 days after the first
vaccination in most of the pigs and at challenge (21
days after the second vaccination) in all of them.
Moreover, neutralizing antibodies were detected in two
animals from group A on day –21 and in four of them
on day 0 (Table 3).
After challenge, all pigs belonging to group B had
seroconverted by day +18 (i.e. 18 days p.c.) and the
titre of neutralizing antibodies reached a maximum
value of 1:32 in one animal from group A and another
from group B at the end of the experiment (Table 3).
All serum samples collected from group C throug-
hout the experiment were negative for PRRSV anti-
bodies.
Discussion
This study assessed the protective response provided
by the commercially available MLV vaccine Amervac-
PRRS® against homologous PRRSV wild-type strain
under experimental conditions. This vaccine is based
on the Spanish PRRSV strain VP046BIS, obtained by
attenuation of the wild-type strain 5710 in MA-104
cell cultures. Amervac-PRRS® is authorized to prevent
respiratory distress caused by PRRSV and vaccination
is prescribed from the fourth week of age. In this
experiment, pigs were vaccinated twice with Amervac-
PRRS® and challenged with the homologous wild-type
strain 5710 of PRRSV three weeks after the second
vaccination. During the whole experimental period,
humoral immune response was determined. The criteria
to evaluate the eff icacy of Amervac-PRRS® were to
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Table 1. Results of virus isolation on swine alveolar macrophages from serum samples collected after challenge
Group Pig
Days of experiment
0 +2 +5 +8 +12 +18
A 1 – – – – – –
2 – – – + – –
3 – – – – – –
4 – – – + – –
5 – – – – – –
6 – + – – – –
Total 0/6a 1/6 0/6 2/6 0/6 0/6
B 7 – + + + + +
8 – + + + + +
9 – + + + + +
10 – + + + + +
11 – + + + + +
12 – + + + + +
Total 0/6 6/6 6/6 6/6 6/6 6/6
C 13 – – – – – –
14 – – – – – –
15 – – – – – –
16 – – – – – –
17 – – – – – –
18 – – – – –
Total 0/6 0/6 0/6 0/6 0/6 0/6
a Positive/tested.
assess the degree of clinical and virological protec-
tion provided by this vaccine.
The results of this study show that pig immunization
with the MLV vaccine Amervac-PRRS® did not produce
any local reaction or side effect. Though, post-vaccinal
viremia was detected from 3 days after the f irst
vaccination to 14 days after the second one. Similar
results have been previously reported after immuni-
zation with other commercial MLV vaccines against
PRRSV such as RespPRRS®, Ingelvac®PRRS ATP and
PorcilisPRRS® (Nodelijk et al., 2001; Pommier et al.,
2003; Johnson et al., 2004; Labarque et al., 2004),
showing that further research should be done in order
to reduce post-vaccinal viremia and, as a result, to
improve current MLV vaccines’ safety.
The results obtained after challenge showed that
animals previously immunized with MLV vaccine
Amervac-PRRS® did not develop any clinical sign or
increase in body temperature associated to PRRSV in-
fection. Resulting from the good health status of the
animals, no detrimental effect on productive parameters
(ADG, food consumption, FCE) was detected. These
results suggest that this MLV vaccine provided high
degree of protection against clinical manifestations of
the disease. However, the mild clinical reactions ob-
served in the infected control group and the difficulties
previously reported to reproduce respiratory symptoms
derived from PRRSV infection under experimental
conditions (van Woensel et al., 1998; Labarque, 1999;
Labarque et al., 2003, 2004) make necessary to evaluate
parameters associated to virological protection.
The results of the present study indicate that MLV
vaccine Amervac-PRRS® was capable of providing re-
markable virological protection against PRRSV infection,
reducing dramatically post-challenge viremia and
preventing PRRSV dissemination to peripheral tissues.
Homologous protection has been previously reported
in other studies after administration of MLV vaccines
such as Ingelvac PRRS® and Prime Pac®, causing absence
of post-challenge viraemia (Hesse et al., 1996; Foss et
al., 2002). Likewise, a complete homologous protection
against PRRSV has been reported after immunization
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Table 2. Results of PRRSV isolation on swine alveolar macrophages from tissue samples
Group Pig
Tissue samples
Retroph-Ln Subm-Ln S-Iliac-Ln Tonsil Kidney Spleen Liver Lung
A 1 – – – – – – – –
2 – – – – – – – –
3 – – – – – – – –
4 – – – – – – – –
5 – – – – – – – –
6 – – – – – – – –
Total 0/6a 0/6 0/6 0/6 0/6 0/6 0/6 0/6
B 7 + + – + – + – +
8 + + + + – – – +
9 – – – + – – – +
10 + + – – – – – –
11 + + – + – – – –
12 + – – + – – – –
Total 5/6 4/6 1/6 5/6 0/6 1/6 0/6 3/6
C 13 – – – – – – – –
14 – – – – – – – –
15 – – – – – – – –
16 – – – – – – – –
17 – – – – – – – –
18 – – – – – – – –
Total 0/6 0/6 0/6 0/6 0/6 0/6 0/6 0/6
a Positive/tested. Retroph-Ln: retropharyngeal lymph node. Subm-Ln: submandibular lymph node. S-Illiac-Ln: superficial iliac
lymph node.
with non-commercial attenuated American PRRSV
isolates (Lager et al., 1999; Mengeling et al., 2003).
Despite clinical and virological protection induced
by immunization with MLV vaccines have been
previously described, little is known about the compo-
nents of the immune system that effectively protect
against PRRSV. In this respect, recent studies high-
lighted the relevance of neutralizing antibodies in
protection against PRRSV in gilts and piglets (Osorio
et al., 2002; López and Osorio, 2004; López et al., 2004).
In the present experiment, neutralizing PRRSV anti-
bodies were detected in pigs of group A 21 days after
the first vaccination. However, no anamnestic response
was observed after the second vaccination or challenge
exposure and the titre of neutralizing antibodies through-
out the study was modest, reaching a maximum value
of 1:32 in one serum collected at the end of the ex-
periment on day +18 (i.e. 18 days p.c.). In the same
way, a moderate post-vaccinal humoral immune
response has been previously described in other
experiments, whose neutralizing antibody titres were
low throughout the whole experimental period (Osorio
et al., 1998; Shibata et al., 2000).
Recent studies have shown that the degree of
protection provided by neutralizing antibodies against
PRRSV infection in young pigs is dose-dependent,
being necessary to reach at challenge a minimum
serum titre of 1:8 to block extra-cellular viremia and
at least 1:32 to get sterilizing immunity (López and
Osorio, 2004; López et al., 2004). Conversely, although
the titre of neutralizing antibodies attained in the
present experiment in group A was ≤ 1:8 at challenge,
extra-cellular viremia was not detected in 50% of the
animals and peripheral tissue dissemination was
completely blocked in all of them. Thus, the titre of
neutralizing antibodies achieved does not seem to be
totally correlated to the level of protection provided
by the MLV vaccine Amervac-PRRS®, suggesting that
a synergic cellular immune response may have been
involved. Actually, although the study of the immunity
against PRRSV has been previously focused on humoral
immune response, characterization of cellular immunity
is being carried out (López et al., 1999; Royaee et al.,
2004; Lowe et al., 2005). Subsequently, a global under-
standing of cellular and humoral immunity against
PRRSV would provide a useful knowledge to develop
new effective vaccines.
In conclusion, the data reported in this study show
that pig immunization with the MLV vaccine Amervac-
PRRS® provides remarkable clinical and virological
protection against homologous PRRSV infection.
However, further research needs to be done in order to
assess the eff iciency of Amervac-PRRS® to reduce
PRRSV transmission, prevent reproductive failure in
pregnant females and provide cross-protection against
heterologous PRRSV strains, as well as to determine
the molecules or cells involved in protective immunity
evolvement.
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